Hyperphosphatemia, or elevated blood phosphorus, is a prevalent issue in chronic kidney disease patients on dialysis, affecting over 80% of this population and linked to higher morbidity and mortality. Clinical guidelines recommend reducing phosphate levels to the 2.5 to 4.5?mg/dL range, and yet an estimated 75% of U.S. dialysis patients remain uncontrolled.
The company we are profiling today is Unicycive Therapeutics Inc. (UNCY), which is developing a treatment for hyperphosphatemia in patients with chronic kidney disease who are on dialysis.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com